The concomitant utilization of buprenorphine and CYP3A4 inducers can reduce the plasma focus of buprenorphine [see CLINICAL PHARMACOLOGY], potentially causing decreased efficacy or onset of the withdrawal syndrome in patients who have produced Bodily dependence to buprenorphine.This is a lot more likely whenever you initial get started treatment or